Protransitnanotherapy
1 known investors
ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.
Investors · 1
Frequently asked questions
- What does Protransitnanotherapy do?
- ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.
- Who are Protransitnanotherapy's investors?
- Protransitnanotherapy's investors include Invest Nebraska.